Atsuo Takashima Selected Research

Chemoradiotherapy

3/2024	Retrospective Analysis of Definitive Chemoradiotherapy With FOLFOX in Patients With Esophageal Cancer Intolerant to Cisplatin.
8/2023	Definitive S-1/mitomycin-C chemoradiotherapy for stage II/III anal canal squamous cell carcinoma: a phase I/II dose-finding and single-arm confirmatory study (JCOG0903).
1/2023	Comparison of clinicopathological and genomic profiles in anal squamous cell carcinoma between Japanese and Caucasian cohorts.
4/2020	Challenges of improving treatment outcomes for colorectal and anal cancers in Japan: the Colorectal Cancer Study Group (CCSG) of the Japan Clinical Oncology Group (JCOG).
1/2020	Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy.
10/2019	Gastric mucosal injury and hemorrhage after definitive chemoradiotherapy for locally advanced esophageal cancer.
7/2019	Chemoradiotherapy for Local Recurrence of Rectal Cancer: A Single Center Study of 18 Patients.
3/2019	Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: Two cases of report.
1/2018	Patterns of Relapse after Definitive Chemoradiotherapy in Stage II/III (Non-T4) Esophageal Squamous Cell Carcinoma.
1/2017	Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Atsuo Takashima Research Topics

Disease

55	Neoplasms (Cancer) 02/2024 - 01/2008
52	Colorectal Neoplasms (Colorectal Cancer) 03/2024 - 01/2009
44	Stomach Neoplasms (Stomach Cancer) 01/2024 - 08/2008
23	Neoplasm Metastasis (Metastasis) 01/2024 - 02/2010
11	Esophageal Squamous Cell Carcinoma 03/2024 - 12/2014
10	Adenocarcinoma 03/2024 - 01/2008
10	Disease Progression 01/2021 - 05/2011
6	Neutropenia 10/2023 - 10/2013
6	Squamous Cell Carcinoma (Epidermoid Carcinoma) 08/2023 - 10/2009
6	Carcinoma (Carcinomatosis) 02/2021 - 04/2015
5	Esophageal Neoplasms (Esophageal Cancer) 03/2024 - 12/2014
4	Rectal Neoplasms (Rectal Cancer) 11/2023 - 05/2017
4	Residual Neoplasm 01/2023 - 02/2009
4	Hemorrhage 04/2021 - 08/2009
3	Hypertension (High Blood Pressure) 01/2024 - 12/2012
3	Colonic Neoplasms (Colon Cancer) 09/2022 - 01/2018
3	Acneiform Eruptions 05/2022 - 01/2019
3	Ascites 12/2020 - 01/2012
3	Anorexia 01/2020 - 08/2010
3	Neuroendocrine Carcinoma 01/2020 - 09/2014
3	Diarrhea 10/2019 - 08/2010
2	Brain Neoplasms (Brain Tumor) 08/2023 - 07/2019
2	Exanthema (Rash) 01/2023 - 09/2016
2	Head and Neck Neoplasms (Head and Neck Cancer) 07/2021 - 03/2019
2	Mesothelioma 03/2021 - 12/2019
2	Malignant Mesothelioma 03/2021 - 12/2019
2	Thrombocytopenia (Thrombopenia) 01/2021 - 01/2020
2	Wounds and Injuries (Trauma) 10/2020 - 04/2015
2	Lung Neoplasms (Lung Cancer) 10/2019 - 06/2009
2	Mucositis 10/2019 - 09/2016
2	Febrile Neutropenia 01/2017 - 08/2010
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2016 - 09/2014
2	Biliary Tract Neoplasms (Biliary Tract Cancer) 09/2013 - 12/2010
2	Nausea 08/2010 - 07/2009
1	COVID-19 02/2024

Drug/Important Bio-Agent (IBA)

20	Cisplatin (Platino)FDA LinkGeneric 03/2024 - 01/2008
18	Fluorouracil (Carac)FDA LinkGeneric 03/2024 - 08/2008
17	Irinotecan (Camptosar)FDA LinkGeneric 01/2023 - 01/2008
16	Bevacizumab (Avastin)FDA Link 03/2024 - 05/2012
12	Oxaliplatin (Eloxatin)FDA LinkGeneric 03/2024 - 12/2012
12	Biomarkers (Surrogate Marker)IBA 02/2024 - 05/2012
11	Panitumumab (Vectibix)FDA Link 02/2024 - 07/2016
11	ErbB Receptors (EGF Receptor)IBA 09/2023 - 01/2009
10	trifluridine tipiracil drug combinationIBA 10/2023 - 01/2018
8	PlatinumIBA 01/2022 - 12/2014
8	regorafenibIBA 01/2022 - 01/2018
7	Cetuximab (Erbitux)FDA Link 03/2024 - 07/2016
7	NivolumabIBA 01/2024 - 01/2019
6	Leucovorin (Folinic Acid)FDA Link 03/2024 - 08/2008
6	Paclitaxel (Taxol)FDA LinkGeneric 04/2020 - 08/2008
5	Docetaxel (Taxotere)FDA Link 03/2024 - 12/2014
5	RamucirumabIBA 07/2023 - 07/2017
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2023 - 02/2009
4	Monoclonal AntibodiesIBA 01/2023 - 01/2018
4	130-nm albumin-bound paclitaxelIBA 01/2020 - 01/2017
3	Immune Checkpoint InhibitorsIBA 01/2023 - 10/2019
3	S-1 plus cisplatinIBA 01/2022 - 12/2013
3	C-Reactive ProteinIBA 11/2021 - 07/2010
3	Taxoids (Taxanes)IBA 03/2021 - 12/2014
3	Trastuzumab (Herceptin)FDA Link 11/2019 - 10/2014
2	Epidermal Growth Factor (EGF)IBA 02/2024 - 09/2022
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2024 - 10/2019
2	Calcibiotic Root Canal SealerIBA 10/2023 - 01/2020
2	Carcinoembryonic AntigenIBA 09/2023 - 10/2016
2	Mitomycin (Mitomycin-C)FDA LinkGeneric 08/2023 - 05/2011
2	Therapeutic UsesIBA 01/2023 - 02/2022
2	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 01/2023
2	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2022 - 07/2021
2	andecaliximabIBA 01/2022 - 01/2022
2	EnzymesIBA 01/2022 - 01/2019
2	ParaffinIBA 04/2021 - 04/2014
2	Formaldehyde (Formol)FDA Link 04/2021 - 04/2014
2	Pemetrexed (MTA)FDA Link 03/2021 - 12/2019
2	Capecitabine (Xeloda)FDA Link 01/2021 - 10/2014
2	SolventsIBA 01/2020 - 01/2017
2	Antineoplastic Agents (Antineoplastics)IBA 08/2019 - 02/2011
2	AntibodiesIBA 01/2019 - 01/2016
2	Serum AlbuminIBA 12/2018 - 07/2010
2	taxaneIBA 09/2017 - 12/2014
2	LigandsIBA 08/2016 - 05/2015
2	Indicators and Reagents (Reagents)IBA 01/2016 - 04/2014
2	Methotrexate (Mexate)FDA LinkGeneric 10/2013 - 02/2010
2	Gemcitabine FDA Link 09/2013 - 12/2010
1	olaparibIBA 03/2024
1	binimetinibIBA 03/2024
1	encorafenibIBA 03/2024
1	VaccinesIBA 02/2024
1	COVID-19 VaccinesIBA 02/2024

Therapy/Procedure

71	Drug Therapy (Chemotherapy) 03/2024 - 01/2008
33	Therapeutics 03/2024 - 08/2008
12	Chemoradiotherapy 03/2024 - 10/2009
7	Gastrectomy 01/2023 - 02/2009
6	Radiotherapy 08/2023 - 08/2009
4	Adjuvant Chemotherapy 05/2021 - 01/2017
4	Combination Drug Therapy (Combination Chemotherapy) 05/2018 - 01/2008
3	Aftercare (After-Treatment) 01/2024 - 01/2014
2	Neoadjuvant Therapy 11/2023 - 08/2018
2	Intravenous Infusions 01/2022 - 02/2011
2	Immunotherapy 01/2021 - 01/2019
2	Esophagectomy 08/2018 - 01/2017